YUFLYMA Drug Profile

Summary for Tradename: YUFLYMA

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for YUFLYMA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for YUFLYMA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for YUFLYMA Derived from Patent Text Search

No patents found based on company disclosures

YUFLYMA: Market Trajectory and Patent Landscape Analysis

Last updated: February 19, 2026

YUFLYMA (adalimumab-axxq) is a biosimilar to Humira (adalimumab), a tumor necrosis factor (TNF) inhibitor used to treat autoimmune diseases. The biosimilar market is characterized by increasing competition and price erosion. YUFLYMA's market performance and patent expiration timeline are critical for R&D and investment decisions.

What is the current market share of YUFLYMA?

As of the most recent reporting periods, YUFLYMA has secured a notable, albeit evolving, market share in the adalimumab biosimilar segment. The U.S. Food and Drug Administration (FDA) approved YUFLYMA in July 2019, making it one of the earlier entrants into the adalimumab biosimilar market. However, the market has since seen a significant influx of competitors, primarily in 2023.

In the United States, the landscape for adalimumab biosimil market share is fragmented and dynamic. Early market entrants, including YUFLYMA, initially captured a portion of the market share from the originator, Humira. However, the expiration of key patents for Humira in mid-2023, coupled with the launch of numerous other adalimumab biosimil products, has led to increased price competition and a shift in market share.

While specific, real-time market share figures for individual biosimil products are often proprietary and subject to rapid change, industry analyses indicate that the collective market share of adalimumab biosimil products in the U.S. has grown substantially. YUFLYMA, as an established player, continues to hold a position within this competitive set. For instance, reports from Q4 2023 and Q1 2024 suggest that biosimil adalimumab products collectively account for a significant percentage of the total adalimumab market, with individual biosimil contributions varying. The specific percentage held by YUFLYMA is influenced by contracting with pharmacy benefit managers (PBMs) and health insurers, as well as physician prescribing patterns. Without access to granular sales data from the manufacturer (Samsung Bioepis) or detailed market research reports, a precise percentage is not publicly quantifiable. However, its presence in multiple formulary listings across major payers indicates ongoing market penetration.

What is the financial trajectory of YUFLYMA?

YUFLYMA's financial trajectory is directly linked to the broader adalimumab biosimilar market dynamics, characterized by initial market entry, increasing competition, and price pressure. As a biosimilar, its revenue generation is dependent on its ability to gain formulary access, secure favorable reimbursement rates, and achieve sales volumes competitive with other adalimumab biosimil products and the originator product.

The period preceding the full market entry of adalimumab biosimil in the U.S. (prior to mid-2023) was marked by anticipation and strategic positioning by manufacturers like Samsung Bioepis, the developer of YUFLYMA. Following its FDA approval in July 2019, YUFLYMA, marketed by Sandoz in the U.S. until its strategic exit from the U.S. biosimil market, was one of the first adalimumab biosimil options available. This early availability allowed it to begin establishing a revenue stream.

The financial performance in the initial years post-launch was likely influenced by limited competition and the process of gaining payer acceptance and physician adoption. However, the true inflection point for YUFLYMA and its competitors arrived in July 2023 with the expiration of primary U.S. patents for Humira, enabling a wave of new biosimilar launches. This event intensified price competition significantly, leading to substantial price reductions across the adalimumab biosimilar class.

YUFLYMA's financial trajectory post-July 2023 is therefore characterized by a sharp increase in competitive pressures and a corresponding decline in average selling prices. Manufacturers are engaged in aggressive contracting with PBMs and integrated delivery networks to secure market share. For YUFLYMA, this means its revenue per unit has decreased, necessitating higher sales volumes to maintain or grow overall revenue. The financial success hinges on its pricing strategy relative to other biosimil entrants, its ability to maintain preferred status on formularies, and the overall market uptake of biosimil adalimumab.

Long-term financial projections are contingent on several factors:

• Sustained Competition: The market is expected to remain highly competitive, with multiple biosimil manufacturers vying for market share.
• Payer Dynamics: Continued negotiation with payers for formulary placement and reimbursement rates will be crucial.
• Physician Adoption: The rate at which physicians switch from originator Humira to biosimil alternatives, including YUFLYMA, will impact sales volume.
• Patent Landscape Evolution: While primary patents have expired, potential litigation or secondary patent challenges could influence market dynamics.
• Global Market Expansion: Expansion into international markets, where patent expiries and biosimilar approvals may differ, will also shape the global financial trajectory.

Without direct financial disclosures from Samsung Bioepis or Sandoz regarding YUFLYMA's specific revenue, precise financial figures are not publicly available. However, industry analysts predict substantial revenue growth for the adalimumab biosimilar class overall, with individual product revenues dictated by market share gains in this fiercely competitive environment. The financial trajectory for YUFLYMA is a balance between increased market access due to lower prices and reduced revenue per unit.

What are the key patents protecting YUFLYMA and Humira?

The patent landscape for adalimumab (Humira) is complex, involving multiple patents covering composition of matter, manufacturing processes, and methods of use. YUFLYMA, as a biosimilar, is designed to be highly similar to Humira. Its development and market entry are contingent upon navigating this patent thicket.

The most critical patents for Humira have historically revolved around:

1. Composition of Matter Patents: These are typically the strongest patents, covering the active pharmaceutical ingredient itself. For adalimumab, these patents have largely expired. The primary composition of matter patent expired in the U.S. in October 2016. However, subsequent patents and legal strategies by the originator extended market exclusivity for Humira.
2. Method of Use Patents: These patents cover specific indications or patient populations for which the drug is approved. Humira has numerous approved indications, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Patents related to these specific uses have been a significant factor in extending Humira's market exclusivity in the U.S.
3. Manufacturing Process Patents: Patents covering novel or improved methods of producing the biologic can also provide protection.
4. Formulation Patents: These patents cover specific drug formulations, such as pre-filled syringes or particular excipients.

For adalimumab biosimil products like YUFLYMA, the key challenge is to demonstrate biosimilarity without infringing on any unexpired, valid patents. The U.S. market experienced significant activity around patent expirations and litigation leading up to the July 2023 launch window.

Key patents and their expiration dates relevant to adalimumab biosimil market entry include:

• U.S. Patent No. 6,096,728: This patent, covering a method of treating inflammatory diseases with TNF inhibitors, expired in October 2018.
• U.S. Patent No. 8,586,023: This patent, relating to the formulation of adalimumab, was a significant focus of litigation. AbbVie had been granted this patent in January 2014. Many biosimilar developers reached settlement agreements to launch their products after its expiration or after agreeing to specific licensing terms. While the patent itself lasted 20 years from its filing date (potentially into 2030s if considering extensions), legal challenges and settlements effectively opened the door for biosimil launches.
• U.S. Patent No. 8,728,481: This patent covers an antibody useful in treating diseases like rheumatoid arthritis. This was another patent subject to litigation and settlement discussions.

The U.S. launch of adalimumab biosimil products, including YUFLYMA, occurred in July 2023. This launch window was enabled by the expiration or settlement of key patents that previously blocked market entry. The specific patent landscape YUFLYMA navigated would have involved detailed analysis of AbbVie's patent portfolio and engagement in potential patent litigation or licensing agreements. The strategy for biosimilar developers is to identify "clean" pathways for market entry, avoiding infringement of any remaining valid patents. Samsung Bioepis, in developing YUFLYMA, would have conducted extensive patent clearance research.

How does YUFLYMA's market entry impact originator sales of Humira?

The market entry of YUFLYMA and other adalimumab biosimil products has a direct and significant impact on the originator sales of Humira (adalimumab). This impact is characterized by market share erosion and price competition.

Prior to the widespread availability of biosimil alternatives, Humira held a dominant position in the treatment of several autoimmune diseases, generating substantial revenue for AbbVie. The U.S. market for Humira was particularly lucrative, representing a significant portion of its global sales.

The introduction of biosimil competitors fundamentally alters this dynamic:

1. Market Share Diversion: As biosimilar options become available and are adopted by healthcare providers and payers, a portion of the patient population previously treated with Humira is switched to a biosimilar. YUFLYMA, as one of the earlier entrants and subsequent competitors, directly contributes to this diversion.
2. Price Erosion: Biosimil products are typically launched at a lower price point than the originator biologic. This price differential is a key driver for payers (insurers, PBMs) to encourage the use of biosimil alternatives to reduce healthcare costs. This leads to increased negotiation leverage for buyers and forces the originator to either lower its price or risk losing significant market share.
3. Contracting and Formulary Placement: Payers often negotiate contracts with biosimilar manufacturers that favor their products through preferred formulary placement. This can result in Humira being less accessible or more expensive for patients and providers, further diminishing its market share.
4. Competitive Dynamics: The U.S. launch in July 2023 saw multiple adalimumab biosimil products enter the market simultaneously. This heightened competition intensifies price pressure and accelerates the shift away from Humira. The presence of several biosimilar options means that Humira faces competition not just from one product but from a suite of alternatives, each vying for market share.

AbbVie has actively managed this transition by introducing its own interchangeable biosimilar of adalimumab, Hyrimoz (adalimumab-adaz), through its subsidiary Alvotech, and by engaging in settlement agreements with biosimilar developers that allowed for earlier launches. Despite these strategies, the overall trend for originator biologics facing biosimilar competition is a significant decline in sales volume and revenue. For Humira, the impact has been a substantial reduction in its U.S. sales following the July 2023 market entry of multiple biosimil competitors.

What are the regulatory hurdles for biosimilar approval and market access?

Securing regulatory approval and achieving broad market access for biosimil drugs like YUFLYMA involves a rigorous and multi-faceted process. These hurdles are designed to ensure the biosimilar is safe, effective, and of comparable quality to the reference biologic, while also navigating complex market dynamics.

Regulatory Hurdles for Approval:

1. Demonstration of Biosimilarity: The core requirement is to demonstrate that the biosimilar is "highly similar" to the reference product, with no clinically meaningful differences in terms of safety, purity, and potency. This involves:
   • Analytical Studies: Extensive head-to-head comparisons of physicochemical properties, biological activity, and structural characteristics.
   • Non-Clinical Studies: In vitro and in vivo studies to assess pharmacokinetic (PK) and pharmacodynamic (PD) properties, immunogenicity, and toxicology.
   • Clinical Studies: Typically, a comparative clinical trial is required in a relevant patient population to confirm similarity in safety and efficacy and to assess immunogenicity. The extent and design of these studies can vary depending on the complexity of the biologic and the analytical data.
2. Manufacturing Process Control: Regulators scrutinize the manufacturing process to ensure consistency and control. Any significant changes in the manufacturing process post-approval can trigger additional regulatory review.
3. Quality and Purity Standards: Biosimil manufacturers must adhere to stringent Good Manufacturing Practices (GMP) and demonstrate consistent product quality and purity.
4. Immunogenicity Assessment: A critical aspect is demonstrating comparable immunogenicity profiles to the reference product. A higher immunogenicity rate can lead to reduced efficacy or increased adverse events.
5. Naming Conventions: The FDA mandates a unique four-letter suffix for biosimil products to distinguish them from their reference products and other biosimil versions, aiding in pharmacovigilance. YUFLYMA's suffix is "-axxq".

Market Access Hurdles:

1. Payer Reimbursement and Formulary Placement: Even after regulatory approval, biosimil manufacturers must secure reimbursement from public and private payers (insurance companies, PBMs). This involves:
   • Health Economic Data: Presenting data on cost-effectiveness and value propositions to payers.
   • Negotiation and Contracting: Engaging in price negotiations and contracting for formulary placement. Biosimil products often need to be priced significantly lower than the originator to gain favorable formulary status.
   • Pharmacy Benefit Managers (PBMs): PBMs play a crucial role in determining which drugs are placed on formularies and at what tier, influencing prescriber and patient choice.
2. Physician Adoption and Prescribing Habits: Healthcare providers must be educated about biosimil products and encouraged to prescribe them. This requires overcoming potential prescriber hesitancy related to unfamiliarity, perceived risks, or established relationships with originator manufacturers.
3. Interchangeability Designation: In the U.S., obtaining an "interchangeable" designation from the FDA allows pharmacists to substitute the biosimilar for the reference product without prescriber intervention, provided state laws permit. YUFLYMA is not currently designated as interchangeable in the U.S. This designation requires additional data, including pharmacokinetic studies demonstrating that predictable and cumulative immunogenicity is unlikely and that efficacy is maintained. Interchangeability significantly enhances market access and sales potential.
4. Competition: The increasing number of biosimilar competitors for a given reference product intensifies market access challenges. Manufacturers must differentiate their product based on price, payer agreements, or other value-added services.
5. Post-Market Surveillance: Continuous monitoring of safety and effectiveness through pharmacovigilance and post-market studies is required to maintain market authorization.

YUFLYMA, like other biosimil adalimumab products, has navigated these regulatory approval pathways. Its ongoing market access success depends on its ability to secure favorable formulary positions and gain physician trust in a competitive marketplace.

What is the competitive landscape for adalimumab biosimil products?

The adalimumab biosimilar market has become one of the most competitive segments within the broader biosimilar landscape. Following the expiration of key patents for AbbVie's Humira in the U.S. in mid-2023, a significant number of biosimilar competitors entered the market, leading to intense price wars and a rapid shift in market share.

Key aspects of the competitive landscape include:

1. High Number of Entrants: The U.S. market saw the simultaneous launch of multiple adalimumab biosimil products in July 2023, including:

   • Amgen's Amjevita (adalimumab-atto)
   • Boehringer Ingelheim's Cyltezo (adalimumab-adbm)
   • Samsung Bioepis' YUFLYMA (adalimumab-axxq) - marketed by Sandoz in the U.S.
   • Organon & BioNTech's Hadlima (adalimumab-aqv)
   • Alvotech/AbbVie's Hyrimoz (adalimumab-adaz) - AbbVie's own interchangeable biosimilar
   • Coherus BioSciences' Cimzia (adalimumab-bwwx) - later renamed Humira (adalimumab-atto)
   • Teva Pharmaceuticals' Truxima (adalimumab-qyyp) - later renamed Humira (adalimumab-adbm)

   Note: Some of the names and suffixes listed above reflect common industry reporting and may vary based on final FDA approval and marketing strategies. The key point is the substantial number of competing products.

2. Price Competition: The influx of multiple biosimil options has triggered aggressive price discounting. Manufacturers are engaged in price wars to secure market share, often offering significant discounts compared to the originator Humira. This has led to a substantial decrease in the average selling price for adalimumab biosimil products.

3. Interchangeability Status: A key differentiator in the U.S. market is the designation of interchangeability. While many adalimumab biosimil products were approved by the FDA, only a subset have sought or achieved interchangeable status. For example, AbbVie's own Hyrimoz and Boehringer Ingelheim's Cyltezo have obtained interchangeable status. This designation allows pharmacists to substitute the biosimilar for Humira without a physician's direct consent, potentially accelerating uptake. YUFLYMA does not currently hold interchangeable status in the U.S.

4. Payer and PBM Influence: Pharmacy benefit managers (PBMs) and insurance companies wield significant influence. They negotiate contracts with biosimilar manufacturers, influencing formulary placement and patient access. Preferred status on formularies, often tied to deep discounts, is crucial for market penetration.

5. Manufacturer Strategies:

   • Samsung Bioepis/Sandoz: YUFLYMA was one of the earlier approved biosimil adalimumab products, giving it a head start. Sandoz, the marketer in the U.S., has been actively involved in contracting.
   • AbbVie: As the originator, AbbVie has responded by launching its own interchangeable biosimilar (Hyrimoz) and has entered into settlement agreements with some biosimilar competitors, which influenced launch timing.
   • Amgen: A major player in the biosimilar space, Amgen has secured interchangeability for Amjevita.
   • Boehringer Ingelheim: Cyltezo also holds interchangeable status.

6. Market Share Dynamics: The market share among adalimumab biosimil products is constantly shifting. The competitive advantages lie with those that secure favorable payer contracts, gain widespread physician adoption, and potentially achieve interchangeable status.

The adalimumab biosimilar market is characterized by a high degree of competition, driven by the large revenue potential of the Humira market and the availability of multiple biosimilar options. This environment necessitates aggressive pricing strategies and robust market access efforts from all manufacturers.

Key Takeaways

• YUFLYMA (adalimumab-axxq) is an adalimumab biosimilar facing an intensely competitive U.S. market following the mid-2023 expiration of key Humira patents.
• Market share for YUFLYMA is dynamic and influenced by contracting with payers and physician adoption amidst a crowded field of biosimilar competitors.
• YUFLYMA's financial trajectory is marked by increasing sales volumes driven by price reductions, as it competes against numerous other adalimumab biosimil products and the originator Humira.
• The patent landscape for adalimumab is complex, with primary composition of matter patents expired. Key method of use and formulation patents were critical barriers that were navigated through expiration or settlement agreements, enabling the July 2023 biosimilar launches.
• YUFLYMA's market entry, alongside other biosimil adalimumab products, has directly led to significant market share erosion and price reductions for originator Humira sales.
• Regulatory approval for biosimil involves demonstrating high similarity to the reference product through extensive analytical, non-clinical, and clinical studies. Market access hurdles include securing payer reimbursement, favorable formulary placement, and physician adoption; YUFLYMA does not currently hold interchangeable status in the U.S.
• The adalimumab biosimilar competitive landscape is characterized by a high number of entrants, aggressive price competition, and significant influence from payers and PBMs.

Frequently Asked Questions

1. When did YUFLYMA receive FDA approval for marketing in the United States? YUFLYMA received FDA approval in July 2019.

2. Is YUFLYMA considered interchangeable with Humira in the U.S. market? No, YUFLYMA is not currently designated as interchangeable with Humira by the FDA.

3. What are the primary autoimmune diseases treated by YUFLYMA? YUFLYMA is indicated for the treatment of conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis, mirroring the indications of its reference product, Humira.

4. Which company is responsible for the development of YUFLYMA? YUFLYMA was developed by Samsung Bioepis.

5. What is the impact of the U.S. launch of multiple adalimumab biosimil products in July 2023 on Humira's market position? The July 2023 launch of numerous adalimumab biosimilar products, including YUFLYMA, has led to substantial market share erosion and significant price competition for Humira, the originator product.

Cited Sources

[1] U.S. Food & Drug Administration. (n.d.). Biosimilar product information page. Retrieved from FDA website (Accessed [Date of Access])

[2] U.S. Patent and Trademark Office. (n.d.). Patent Search Database. Retrieved from [USPTO website](https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetacgi%2Fnph-Parser%3 D.Sect1%3DAGR%26Sect2%3DHITOFF%26p%3D1%26u%3D%252Fn etacgi%252Fnph-Parser%253FSect1%3D AGR%26Sect2%3DHITOFF%26d%3DPG01%26S rch Term%3D%22adalimumab%22%26Sort%3D